European Heart Journal · 2018 · 90 citations · 26 references
MedicineCardiologyPharmacotherapyCardiovascular PharmacotherapyClinical CardiologyClinical EpidemiologyCardiac MedicationsCardiovascular DiseaseCardiovascular Disease PreventionCoronary Artery DiseaseIschemic Heart DiseaseBeta-adrenergic Blocker UseBeta-blocker Therapy ManagementBeta-blocker UseCoronary Artery Disease PharmacotherapyMultivariable AdjustmentPrimary Outcome Analysis
AIMS: The effect of first-line antianginal agents, β-blockers, and calcium antagonists on clinical outcomes in stable coronary artery disease (CAD) remains uncertain. METHODS AND RESULTS: We analysed the use of β-blockers or calcium antagonists (baseline and annually) and outcomes in 22 006 stable CAD patients (enrolled 2009-2010) followed annually to 5 years, in the CLARIFY registry (45 countries). Primary outcome was all-cause death. Secondary outcomes were cardiovascular death and the composite of cardiovascular death/non-fatal myocardial infarction (MI). After multivariable adjustment, baseline β-blocker use was not associated with lower all-cause death [1345 (7.8%) in users vs. 407 (8.4%) in non-users; hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.84-1.06; P = 0.30]; cardiovascular death [861 (5.0%) vs. 262 (5.4%); HR 0.91, 95% CI 0.79-1.05; P = 0.20]; or cardiovascular death/non-fatal MI [1272 (7.4%) vs. 340 (7.0%); HR 1.03, 95% CI 0.91-1.16; P = 0.66]. Sensitivity analyses according to β-blocker use over time and to prescribed dose produced similar results. Among prior MI patients, for those enrolled in the year following MI, baseline β-blocker use was associated with lower all-cause death [205 (7.0%) vs. 59 (10.3%); HR 0.68, 95% CI 0.50-0.91; P = 0.01]; cardiovascular death [132 (4.5%) vs. 49 (8.5%); HR 0.52, 95% CI 0.37-0.73; P = 0.0001]; and cardiovascular death/non-fatal MI [212 (7.2%) vs. 59 (10.3%); HR 0.69, 95% CI 0.52-0.93; P = 0.01]. Calcium antagonists were not associated with any difference in mortality. CONCLUSION: In this contemporary cohort of stable CAD, β-blocker use was associated with lower 5-year mortality only in patients enrolled in the year following MI. Use of calcium antagonists was not associated with superior mortality, regardless of history of MI.
26
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial
The Lancet · 1999 · 4.9K citations
Medicine, Cardiology, Pharmacology +10
2013 ESC guidelines on the management of stable coronary artery disease
Héctor Bueno · European Heart Journal · 2013 · 4.5K citations · Full text